Adults 18 to 60, male only, with Radiculopathy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Visual Analog ScalePrimary· The measurements were taken at days "0,1,5,12"
Visual analog scale was used to measure pain intensity. This scale is a 10 cm line where patients chose from 0 to 10 (when 0 mean no pain and 10 mean maximum pain)
Basline
Group
Value
95% CI
Control Group
5.638
± 1.75762
Slider Group
5.050
± 2.15029
Tensioner Group
5.094
± 1.95015
After 1st Day
Group
Value
95% CI
Control Group
4.894
± 1.86001
Slider Group
4.759
± 1.99125
Tensioner Group
3.576
± 2.22810
After 5th Day
Group
Value
95% CI
Control Group
5.100
± 1.87508
Slider Group
3.556
± 2.21613
Tensioner Group
2.606
± 2.02005
After 12th Day
Group
Value
95% CI
Control Group
4.665
± 1.74676
Slider Group
2.626
± 2.23538
Tensioner Group
2.082
± 1.56734
Hip Flexion Range of Motion (Symptomatic Side)Primary· The measurements were taken at days "0,1,5,12"
Change in Hip flexion range of motion during straight leg raising (symptomatic side)
Baseline
Group
Value
95% CI
Control Group
51.82
± 15.314
Slider Group
57.71
± 16.042
Tensioner Group
46.29
± 16.243
After 1st Day
Group
Value
95% CI
Control Group
58.53
± 13.884
Slider Group
63.59
± 15.452
Tensioner Group
58.88
± 16.714
After 5th Day
Group
Value
95% CI
Control Group
59.24
± 14.338
Slider Group
67.47
± 15.412
Tensioner Group
62.82
± 13.956
After 12th Day
Group
Value
95% CI
Control Group
57.71
± 17.944
Slider Group
74.41
± 22.327
Tensioner Group
68.59
± 12.555
Knee Flexion Range of Motion (Symptomatic Side)Primary· The measurements were taken at days "0,1,5,12"
Change in Knee flexion range of motion during slump (symptomatic side)
Baseline
Group
Value
95% CI
Control Group
52.29
± 17.395
Slider Group
45.647
± 18.435
Tensioner Group
47.059
± 14.545
After 1st Day
Group
Value
95% CI
Control Group
49.41
± 17.603
Slider Group
31.294
± 12.133
Tensioner Group
34.824
± 15.509
After 5th Day
Group
Value
95% CI
Control Group
48
± 14.018
Slider Group
31.412
± 14.590
Tensioner Group
31.765
± 14.342
After 12th Day
Group
Value
95% CI
Control Group
47
± 16.733
Slider Group
26.882
± 15.419
Tensioner Group
64.47
± 25.529
Hip Flexion Range of Motion (Asymptomatic Side)Primary· The measurements were taken at days "0,1,5,12"
Change in Hip Flexion Range of Motion During Straight Leg Raising (Asymptomatic Side)
Baseline
Group
Value
95% CI
Control Group
70.00
± 15.313
Slider Group
71.824
± 20.467
Tensioner Group
63.59
± 15.407
After 1st Day
Group
Value
95% CI
Control Group
69.41
± 17.044
Slider Group
70.82
± 20.944
Tensioner Group
69.12
± 13.114
After 5th Day
Group
Value
95% CI
Control Group
71.12
± 11.146
Slider Group
74.12
± 18.721
Tensioner Group
72.12
± 11.033
After 12th Day
Group
Value
95% CI
Control Group
73.06
± 12.920
Slider Group
74.88
± 19.251
Tensioner Group
72.47
± 10.869
Knee Flexion Range of Motion (Asymptomatic Side)Primary· The measurements were taken at days "0,1,5,12"
Change in Knee flexion range of motion during slump (Asymptomatic side)
Baseline
Group
Value
95% CI
Control Group
31.1176
± 19.70052
Slider Group
31.7059
± 12.01439
Tensioner Group
28.8824
± 18.01001
After 1st Day
Group
Value
95% CI
Control Group
30.41
± 22.319
Slider Group
24.06
± 13.831
Tensioner Group
26.06
± 14.528
After 5th Day
Group
Value
95% CI
Control Group
28.94
± 18.216
Slider Group
28.76
± 19.250
Tensioner Group
23.88
± 13.453
After 12th Day
Group
Value
95% CI
Control Group
24.88
± 17.517
Slider Group
22.29
± 16.669
Tensioner Group
20.35
± 12.639
Sponsor's own description
The primary purpose of this study was to investigate the effects of slider and tensioner techniques on pain, hip and knee ROM in lumbosacral radiculopathy patients with peripheral sensitization. A secondary purpose was to evaluate the correlation between these outcomes measurements.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mohammed Al-Ghamdi
Last refreshed: 1 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03621878.